Developer docs
API playgroundTry for free, no card

Search company profiles

OWP Pharmaceuticals

Full company profile

uuid0000dre

Namestring
OWP Pharmaceuticals
Legal namestring
OWP Pharmaceuticals, Inc.
Websiteurl
owppharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company founded in 2014 and headquartered in Naperville, Illinois. The company develops novel oral liquid formulations of already-approved therapeutics via the FDA's 505(b)(2) regulatory pathway, targeting indications where no liquid formulation currently exists — primarily epilepsy, bipolar disorder, schizophrenia, ADHD, and major depressive disorder. Its core technology is formulation chemistry that converts existing tablet or capsule drugs into oral suspensions, oral solutions, or powders-for-oral-liquid, with first-to-market filings protected by patents and FDA approvals.

The company's commercial portfolio includes SUBVENITE (lamotrigine) oral suspension — the first liquid formulation of lamotrigine in the United States, FDA-approved September 2025 and commercially launched January 2026 — along with SUBVENITE lamotrigine tablets, generic Lamotrigine Starter Kits (Orange/Blue/Green titration packs), and Roweepra IR (levetiracetam). A pipeline of four additional oral liquid candidates (quetiapine fumarate, atomoxetine HCl, duloxetine HCl, and trazodone HCl) is at various IND- and patent-stage milestones. Revenue is generated through prescription pharmaceutical sales to U.S. healthcare providers in neurology and psychiatry, distributed via standard pharmacy and specialty distributor channels and supported by a commercialization partnership with EVERSANA (originally 2022, expanded October 2025) that provides market access, field sales, and patient services.

OWP operates under a distinctive "Pharmaceutical Social Enterprise 2.0" model in which a portion of profits is donated to ROW Global/ROW Foundation, a public charity that has sponsored more than 140,000 patient prescription months of anti-seizure medication in under-resourced areas worldwide. The company employs 11–50 people and is led by founder and President Scott Boyer (formerly of Abbott and Bristol-Myers Squibb), alongside COO Mary Dunham, CFO Steve Bourne, and CCO Sara Gao.

Short descriptiontext

OWP Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that develops and commercializes novel oral liquid formulations of approved neuroscience drugs via the FDA 505(b)(2) pathway, serving neurology and psychiatry prescribers and their epilepsy, bipolar, and psychiatric patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLisle, United States
HQ citystring
Lisle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral liquid formulations, neuroscience specialty pharma, 505(b)(2) drug development, branded generic epilepsy drugs, lamotrigine oral suspension
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Neuroscience specialty pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

OWP generates revenue through the sale of branded generic pharmaceuticals including SUBVENITE (lamotrigine tablets and oral suspension), Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). Products are sold to healthcare providers and through pharmaceutical distribution channels.

owppharma.com
2Humanitarian Donations Model
TypeSubscription Recurring
Description

A portion of profits is donated to ROW Global/ROW Foundation to support humanitarian efforts in under-resourced areas, supporting epilepsy treatment globally. This is a unique Social Enterprise 2.0 model where commercial success funds philanthropy.

owppharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Pricing details1 tier
1Prescription pharmaceutical products sold to healthcare providers and patients
ModelOther
Notes

Pricing not publicly disclosed - products sold through healthcare providers with insurance coverage and pharmacy benefit manager negotiations determining patient cost.

owppharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Subvenite
Description

Brand name for lamotrigine products including tablets and oral suspension, used for epilepsy and bipolar disorder treatment. Subvenite is OWP's branded generic alternative (AB rated) to Lamictal Starter Kits.

owppharma.com
+2 more records
Core offering1 text field

OWP Pharmaceuticals develops, manufactures, and commercializes novel oral liquid formulations of approved neuroscience therapeutics under the FDA 505(b)(2) pathway, including SUBVENITE (lamotrigine) tablets and oral suspension, Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). The company sells these prescription pharmaceutical products to U.S. healthcare providers and through pharmaceutical distribution channels, while operating a Pharmaceutical Social Enterprise model that directs a portion of profits to ROW Global for humanitarian epilepsy programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First liquid formulation of lamotrigine approved in the U.S. (FDA September 2025)
+2 more records
Product overview1 text field

OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company dedicated to developing and commercializing novel oral liquid formulations. The company operates a dual product portfolio: (1) Currently commercialized products including SUBVENITE (lamotrigine) in both tablet starter kits and oral suspension formulations, generic Lamotrigine Starter Kits, and Roweepra IR (levetiracetam); and (2) A pipeline of reformulated approved therapeutics with no currently available liquid formulations including quetiapine fumarate, trazodone hydrochloride, atomoxetine hydrochloride, and duloxetine hydrochloride, being developed via 505(b)(2) applications for neuroscience conditions such as epilepsy, bipolar disorder, schizophrenia, migraine, ADHD, and depression. OWP's business model involves donating profits to ROW Global for humanitarian purposes supporting epilepsy treatment in under-resourced areas worldwide.

Product and service4 records
1SUBVENITE (lamotrigine) Oral Suspension
CategoryBranded generic pharmaceutical (oral liquid)
Description

First FDA-approved oral liquid formulation of lamotrigine in the U.S., designed for patients with swallowing challenges and those needing tailored dosing for epilepsy and bipolar disorder. Prescribed by U.S. healthcare providers in neurology and psychiatry.

2SUBVENITE (lamotrigine tablets, USP) Starter Kits
CategoryBranded generic pharmaceutical (starter kit)
Description

Branded generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits, offered in Orange, Blue, and Green kits based on FDA-approved 5-week titration schedules for patients initiating lamotrigine therapy for epilepsy or bipolar disorder.

3Lamotrigine Starter Kits
CategoryGeneric pharmaceutical (starter kit)
Description

Generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits, offered as part of OWP's branded generic portfolio for epilepsy treatment, supplied in Orange, Blue, and Green kits for FDA-approved titration schedules.

4Roweepra IR (Levetiracetam)
CategoryBranded generic pharmaceutical (anti-epileptic)
Description

Anti-epileptic medication (levetiracetam immediate release) marketed by OWP for the treatment of epilepsy, part of the company's neuroscience medication portfolio.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-10-23
Description

In October 2025, OWP selected EVERSANA to provide commercialization services for the U.S. launch of SUBVENITE (lamotrigine) oral suspension. This partnership aims to improve access for patients who have difficulty swallowing tablets and is part of a broader partnership targeting global epilepsy treatment access. EVERSANA's commercialization services support market entry and patient reach.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-05
Description

In January 2022, OWP partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed at treating neuroscience disorders. EVERSANA provides fully integrated commercialization services including market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, all optimized by data and predictive analytics. In October 2025, EVERSANA was selected to support the U.S. launch of SUBVENITE oral suspension.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

OWP Pharmaceuticals enjoys an innovative relationship with ROW Global through its hybrid Pharmaceutical Social Enterprise business model. Together they form a concerted organization with shared goals and values. OWP uses commercial success for the common good by supporting humanitarian projects rather than solely maximizing profits. A large portion of OWP profits goes to provide resources for those living with neurological disorders in under-resourced areas of the world. ROW Global has sponsored dozens of programs and granted more than 140,000 patient prescription months of anti-seizure medication. Income to the foundation is directly linked to OWP sales revenues.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Jazz Pharmaceuticals is an established specialty pharma company with a significant neurology/CNS portfolio (epilepsy treatments including Xywav, Epidiolex). Comparable as a CNS-focused commercial-stage specialty pharma with branded reformulation strategies and global commercial reach — Jazz represents what OWP could aspire to become at scale.

TypeDirect peer
Description

Supernus is a CNS specialty pharma focused on epilepsy and ADHD (Trokendi XR, Oxtellar XR, Qelbree). Highly comparable to OWP given its neuroscience-only focus, branded specialty formulations of established molecules, and similar patient/provider target audience.

TypeDirect peer
Description

Upsher-Smith is a private specialty/generic pharma with strong CNS presence (lamotrigine, levetiracetam, quetiapine). Direct competitor to OWP in the same molecules and therapeutic categories, with similar reformulation/improved-formulation strategy targeting neuroscience prescribers.

TypeEmerging player
Description

Aquestive is a specialty pharma focused on novel delivery formats (oral films, sublingual) for CNS conditions. Comparable as a small-cap CNS-focused company using novel formulation approaches (similar to OWP's 505(b)(2) liquid strategy) to differentiate mature molecules.

TypeEmerging player
Description

Neos Therapeutics developed extended-release and orally disintegrating ADHD/CNS medications. Comparable as a small specialty pharma using novel/reformulated CNS delivery formats and pursuing similar prescriber channels (psychiatrists, neurologists).

TypeBroad incumbent
Description

Lundbeck is a global specialty pharma fully dedicated to brain diseases (epilepsy, depression, psychiatry). Comparable as a CNS-focused specialty pharma with branded neuroscience products targeting the same prescriber base as OWP, but at much larger global scale.

TypeBroad incumbent
Description

UCB is a global biopharma with a strong neurology portfolio (Vimpat/lacosamide, Keppra/levetiracetam, Briviact). Comparable as a neuroscience-focused company with branded epilepsy products competing in the same prescriber market as OWP's lamotrigine/levetiracetam portfolio.

TypeBroad incumbent
Description

Eisai has a significant neurology franchise including epilepsy treatments (Fycompa, Banzel). Comparable as an established neuroscience pharma with branded CNS products in the same therapeutic categories (epilepsy) as OWP's portfolio.

TypeDirect peer
Description

Zydus is a global generic/specialty pharma with significant U.S. CNS offerings including lamotrigine and levetiracetam. Comparable as a competing manufacturer/distributor of generic lamotrigine and levetiracetam products in the same therapeutic space as OWP's Roweepra and Lamotrigine Starter Kits.

10Camden Group
TypeOthers
Description

ROW Foundation/ROW Global Health is OWP's nonprofit sister organization, funding humanitarian epilepsy treatment globally (140,000+ patient prescription months sponsored). While not a commercial peer, it is a unique ecosystem partner embedded in OWP's social enterprise model and a key element of the company's brand positioning.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OWP Pharmaceuticals

Neuroscience specialty pharmaceuticalsowppharma.com

OWP Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that develops and commercializes novel oral liquid formulations of approved neuroscience drugs via the FDA 505(b)(2) pathway, serving neurology and psychiatry prescribers and their epilepsy, bipolar, and psychiatric patients.

What OWP Pharmaceuticals does

OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company founded in 2014 and headquartered in Naperville, Illinois. The company develops novel oral liquid formulations of already-approved therapeutics via the FDA's 505(b)(2) regulatory pathway, targeting indications where no liquid formulation currently exists — primarily epilepsy, bipolar disorder, schizophrenia, ADHD, and major depressive disorder. Its core technology is formulation chemistry that converts existing tablet or capsule drugs into oral suspensions, oral solutions, or powders-for-oral-liquid, with first-to-market filings protected by patents and FDA approvals.

The company's commercial portfolio includes SUBVENITE (lamotrigine) oral suspension — the first liquid formulation of lamotrigine in the United States, FDA-approved September 2025 and commercially launched January 2026 — along with SUBVENITE lamotrigine tablets, generic Lamotrigine Starter Kits (Orange/Blue/Green titration packs), and Roweepra IR (levetiracetam). A pipeline of four additional oral liquid candidates (quetiapine fumarate, atomoxetine HCl, duloxetine HCl, and trazodone HCl) is at various IND- and patent-stage milestones. Revenue is generated through prescription pharmaceutical sales to U.S. healthcare providers in neurology and psychiatry, distributed via standard pharmacy and specialty distributor channels and supported by a commercialization partnership with EVERSANA (originally 2022, expanded October 2025) that provides market access, field sales, and patient services.

OWP operates under a distinctive "Pharmaceutical Social Enterprise 2.0" model in which a portion of profits is donated to ROW Global/ROW Foundation, a public charity that has sponsored more than 140,000 patient prescription months of anti-seizure medication in under-resourced areas worldwide. The company employs 11–50 people and is led by founder and President Scott Boyer (formerly of Abbott and Bristol-Myers Squibb), alongside COO Mary Dunham, CFO Steve Bourne, and CCO Sara Gao.

OWP Pharmaceuticals firmographics

Firmographics
Name
OWP Pharmaceuticals
Legal name
OWP Pharmaceuticals, Inc.
Website
https://owppharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
OWP Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that develops and commercializes novel oral liquid formulations of approved neuroscience drugs via the FDA 505(b)(2) pathway, serving neurology and psychiatry prescribers and their epilepsy, bipolar, and psychiatric patients.
Ownership category
akta.pro rank

OWP Pharmaceuticals industry classification

Industry
Product category
Neuroscience specialty pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Oral liquid formulations
  • Neuroscience specialty pharma
  • 505(b)(2) drug development
  • Branded generic epilepsy drugs
  • Lamotrigine oral suspension

Where OWP Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Lisle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

OWP Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Pharmaceutical Product Sales: OWP generates revenue through the sale of branded generic pharmaceuticals including SUBVENITE (lamotrigine tablets and oral suspension), Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). Products are sold to healthcare providers and through pharmaceutical distribution channels.
  2. Humanitarian Donations Model: A portion of profits is donated to ROW Global/ROW Foundation to support humanitarian efforts in under-resourced areas, supporting epilepsy treatment globally. This is a unique Social Enterprise 2.0 model where commercial success funds philanthropy.

Pricing tiers

ModelBillingPrice
Other—Prescription pharmaceutical products sold to healthcare providers and patients

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

OWP Pharmaceuticals product offering

Product offering

Core offering

OWP Pharmaceuticals develops, manufactures, and commercializes novel oral liquid formulations of approved neuroscience therapeutics under the FDA 505(b)(2) pathway, including SUBVENITE (lamotrigine) tablets and oral suspension, Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). The company sells these prescription pharmaceutical products to U.S. healthcare providers and through pharmaceutical distribution channels, while operating a Pharmaceutical Social Enterprise model that directs a portion of profits to ROW Global for humanitarian epilepsy programs.

Product overview

OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company dedicated to developing and commercializing novel oral liquid formulations. The company operates a dual product portfolio: (1) Currently commercialized products including SUBVENITE (lamotrigine) in both tablet starter kits and oral suspension formulations, generic Lamotrigine Starter Kits, and Roweepra IR (levetiracetam); and (2) A pipeline of reformulated approved therapeutics with no currently available liquid formulations including quetiapine fumarate, trazodone hydrochloride, atomoxetine hydrochloride, and duloxetine hydrochloride, being developed via 505(b)(2) applications for neuroscience conditions such as epilepsy, bipolar disorder, schizophrenia, migraine, ADHD, and depression. OWP's business model involves donating profits to ROW Global for humanitarian purposes supporting epilepsy treatment in under-resourced areas worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Subvenite: Brand name for lamotrigine products including tablets and oral suspension, used for epilepsy and bipolar disorder treatment. Subvenite is OWP's branded generic alternative (AB rated) to Lamictal Starter Kits.
  • Subvenite Oral Suspension
  • Roweepra IR

Products and services

  • SUBVENITE (lamotrigine) Oral Suspension First FDA-approved oral liquid formulation of lamotrigine in the U.S., designed for patients with swallowing challenges and those needing tailored dosing for epilepsy and bipolar disorder. Prescribed by U.S. healthcare providers in neurology and psychiatry.
  • SUBVENITE (lamotrigine tablets, USP) Starter Kits Branded generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits, offered in Orange, Blue, and Green kits based on FDA-approved 5-week titration schedules for patients initiating lamotrigine therapy for epilepsy or bipolar disorder.
  • Lamotrigine Starter Kits Generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits, offered as part of OWP's branded generic portfolio for epilepsy treatment, supplied in Orange, Blue, and Green kits for FDA-approved titration schedules.
  • Roweepra IR (Levetiracetam) Anti-epileptic medication (levetiracetam immediate release) marketed by OWP for the treatment of epilepsy, part of the company's neuroscience medication portfolio.

Quantifiable outcome

  • First liquid formulation of lamotrigine approved in the U.S. (FDA September 2025)
  • +2 more outcomes

Companies that use OWP Pharmaceuticals

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

OWP Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

OWP Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • EVERSANAcoreGTM or Marketing Partner · 23 October 2025In October 2025, OWP selected EVERSANA to provide commercialization services for the U.S. launch of SUBVENITE (lamotrigine) oral suspension. This partnership aims to improve access for patients who have difficulty swallowing tablets and is part of a broader partnership targeting global epilepsy treatment access. EVERSANA's commercialization services support market entry and patient reach.
  • EVERSANAcoreChannel Partner/ Reseller/ Distributor · 5 January 2022In January 2022, OWP partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed at treating neuroscience disorders. EVERSANA provides fully integrated commercialization services including market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, all optimized by data and predictive analytics. In October 2025, EVERSANA was selected to support the U.S. launch of SUBVENITE oral suspension.
  • ROW Global/ROW FoundationcoreStrategic or Co-development Partner · 1 January 2014OWP Pharmaceuticals enjoys an innovative relationship with ROW Global through its hybrid Pharmaceutical Social Enterprise business model. Together they form a concerted organization with shared goals and values. OWP uses commercial success for the common good by supporting humanitarian projects rather than solely maximizing profits. A large portion of OWP profits goes to provide resources for those living with neurological disorders in under-resourced areas of the world. ROW Global has sponsored dozens of programs and granted more than 140,000 patient prescription months of anti-seizure medication. Income to the foundation is directly linked to OWP sales revenues.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

OWP Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is an established specialty pharma company with a significant neurology/CNS portfolio (epilepsy treatments including Xywav, Epidiolex). Comparable as a CNS-focused commercial-stage specialty pharma with branded reformulation strategies and global commercial reach — Jazz represents what OWP could aspire to become at scale.
  • Lundbeck: Lundbeck is a global specialty pharma fully dedicated to brain diseases (epilepsy, depression, psychiatry). Comparable as a CNS-focused specialty pharma with branded neuroscience products targeting the same prescriber base as OWP, but at much larger global scale.
  • UCB: UCB is a global biopharma with a strong neurology portfolio (Vimpat/lacosamide, Keppra/levetiracetam, Briviact). Comparable as a neuroscience-focused company with branded epilepsy products competing in the same prescriber market as OWP's lamotrigine/levetiracetam portfolio.
  • Eisai (U.S. neurology operations): Eisai has a significant neurology franchise including epilepsy treatments (Fycompa, Banzel). Comparable as an established neuroscience pharma with branded CNS products in the same therapeutic categories (epilepsy) as OWP's portfolio.

Direct peers

  • Supernus Pharmaceuticals: Supernus is a CNS specialty pharma focused on epilepsy and ADHD (Trokendi XR, Oxtellar XR, Qelbree). Highly comparable to OWP given its neuroscience-only focus, branded specialty formulations of established molecules, and similar patient/provider target audience.
  • Upsher-Smith Laboratories: Upsher-Smith is a private specialty/generic pharma with strong CNS presence (lamotrigine, levetiracetam, quetiapine). Direct competitor to OWP in the same molecules and therapeutic categories, with similar reformulation/improved-formulation strategy targeting neuroscience prescribers.
  • Zydus Pharmaceuticals USA: Zydus is a global generic/specialty pharma with significant U.S. CNS offerings including lamotrigine and levetiracetam. Comparable as a competing manufacturer/distributor of generic lamotrigine and levetiracetam products in the same therapeutic space as OWP's Roweepra and Lamotrigine Starter Kits.

Emerging players

  • Aquestive Therapeutics: Aquestive is a specialty pharma focused on novel delivery formats (oral films, sublingual) for CNS conditions. Comparable as a small-cap CNS-focused company using novel formulation approaches (similar to OWP's 505(b)(2) liquid strategy) to differentiate mature molecules.
  • Neos Therapeutics: Neos Therapeutics developed extended-release and orally disintegrating ADHD/CNS medications. Comparable as a small specialty pharma using novel/reformulated CNS delivery formats and pursuing similar prescriber channels (psychiatrists, neurologists).

Others

  • Camden Group: ROW Foundation/ROW Global Health is OWP's nonprofit sister organization, funding humanitarian epilepsy treatment globally (140,000+ patient prescription months sponsored). While not a commercial peer, it is a unique ecosystem partner embedded in OWP's social enterprise model and a key element of the company's brand positioning.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

OWP Pharmaceuticals social profiles

Digital presence

OWP Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OWP Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

OWP Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OWP Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OWP Pharmaceuticals

What does OWP Pharmaceuticals do?

OWP Pharmaceuticals develops, manufactures, and commercializes novel oral liquid formulations of approved neuroscience therapeutics under the FDA 505(b)(2) pathway, including SUBVENITE (lamotrigine) tablets and oral suspension, Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). The company sells these prescription pharmaceutical products to U.S. healthcare providers and through pharmaceutical distribution channels, while operating a Pharmaceutical Social Enterprise model that directs a portion of profits to ROW Global for humanitarian epilepsy programs.

Is OWP Pharmaceuticals a public or private company?

OWP Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OWP Pharmaceuticals founded?

OWP Pharmaceuticals was founded in 2014. It employs 11 to 50 people.

Where is OWP Pharmaceuticals based?

OWP Pharmaceuticals is headquartered in Lisle, United States, in the North America region.

How does OWP Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are humanitarian Donations Model.

Who are OWP Pharmaceuticals's main competitors?

Broad incumbents on record are Jazz Pharmaceuticals, Lundbeck, UCB and Eisai (U.S. neurology operations). Direct peers are Supernus Pharmaceuticals, Upsher-Smith Laboratories and Zydus Pharmaceuticals USA. Emerging players are Aquestive Therapeutics and Neos Therapeutics. Camden Group is listed as an others.

Does OWP Pharmaceuticals have an API?

No public API is recorded for OWP Pharmaceuticals.

What industry is OWP Pharmaceuticals in?

OWP Pharmaceuticals's product category is Neuroscience specialty pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Stockton RecordOWP Pharmaceuticals Announces Commercial Product Availability of SUBVENITE® (lamotrigine) Oral Suspension in U.S. MarketOWP Pharmaceuticals announced the commercial availability of SUBVENITE® (lamotrigine) oral suspension in the U.S. after receiving FDA approval in September 2025. This product is the first liquid formulation of lamotrigine in the U.S. and aims to improve treatment options for patients with swallowing challenges and those needing tailored dosing.PharmiWeb.comOWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE® (lamotrigine) Oral SuspensionOWP Pharmaceuticals announced that EVERSANA will provide U.S. commercialization services for SUBVENITE® (lamotrigine) oral suspension, a novel treatment for epilepsy and bipolar disorders that received FDA approval on September 16, 2025. SUBVENITE® is the first and only FDA-approved lamotrigine oral suspension in the U.S., designed as a patient-friendly alternative to tablets for those with difficulty swallowing or who require individualized dosing. EVERSANA will activate field deployment, data & analytics, and co-pay services to support the product launch under a broader partnership established in January 2022.PR NewswireOWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE® (lamotrigine) Oral SuspensionOWP Pharmaceuticals announced that EVERSANA will provide U.S. commercialization services for the launch of SUBVENITE® (lamotrigine) oral suspension, which received FDA approval on September 16, 2025. SUBVENITE® is the first and only FDA-approved lamotrigine oral suspension in the U.S., offering a patient-friendly liquid alternative to tablets for epilepsy and bipolar disorder patients who have difficulty swallowing. The launch support extends a broader commercialization partnership between the two companies that was first announced in January 2022.SecSEC FORM DOWP Pharmaceuticals, Inc. filed a Form D with the SEC to report an exempt offering of equity securities under Rule 506(b). The company raised a total of $2,730,773 from 11 investors, with all funds sold by the first sale date of June 5, 2024. This regulatory filing discloses the completion of a private capital raise for the Illinois-based pharmaceutical firm.PR NewswireOWP Pharmaceuticals, Twinned with a Not-For-Profit (ROW Foundation) Focuses on Affordable Access to Select Neuro/Psych Neuroscience DrugsOWP Pharmaceuticals, an angel investor-backed pharmaceutical startup founded in 2014 in Naperville, Illinois, launched in 2017 with branded generic epilepsy medications Roweepra™ and Roweepra XR™, with Subvenite™ (lamotrigine) slated for launch in multiple dosages including Starter Kits. The company pioneered a dual business model that simultaneously markets prescription drugs in the US while funding humanitarian donations of the same medications to developing countries through its affiliated ROW (Rest of World) Foundation, a 501(c)(3) not-for-profit endowed with Founder's Stock by OWP's co-founders Scott Boyer and Bruce Duncan. The ROW Foundation aims to relieve human suffering by providing access to neurology and psychiatry medications in select developing nations, with Armenia cited as one beneficiary country.